0001736297-25-000098
SEC filingRevenue surged 147% YoY to $351M in H1 2025 driven by strong demand for Aries, Scorpio, and Taurus, while gross margin contracted 230 bps to 75.4%.
For the six months ended June 30, 2025, Astera Labs reported robust revenue growth of 147% to $351.4 million, compared to $142.1 million in the same period of 2024. The increase was primarily driven by higher unit shipments of Aries, Scorpio, and Taurus products, along with higher average selling prices from a mix shift toward hardware modules and Scorpio products. Gross profit rose 140% to $265.0 million, but gross margin declined 230 basis points to 75.4% due to the same product mix shift. Operating income improved dramatically from a loss of $107.3 million to income of $51.1 million, reflecting lower stock-based compensation expense after the IPO and strong revenue scalability. Net income swung from a loss of $100.5 million to income of $83.0 million.
Astera Labs does not report formal segment revenue, but management cited that revenue growth was driven by strong demand across its product families: Aries (retimers and cable modules), Scorpio (smart fabric switches), and Taurus (Ethernet cable modules). The product mix shifted toward hardware modules and Scorpio products, which contributed to higher average selling prices but also pressured gross margin due to higher cost of goods sold. Research and development expenses increased 40% to $131.3 million, reflecting a 96% increase in R&D headcount and investments in new product development. Sales and marketing expenses declined 48% due to lower stock-based compensation, while general and administrative expenses decreased 9%.
Management highlighted continued investment in R&D and headcount expansion to support future growth. The company reported a healthy cash position of $1,065.1 million in cash, cash equivalents, and marketable securities, and generated $145.9 million in operating cash flow during the first half of 2025. While no formal guidance was provided, the strong revenue momentum and significant operating leverage suggest potential for continued profitability improvement. Risks include the impact of product mix on margins and the need for sustained demand from hyperscaler customers.
As of June 30, 2025, the company held $162.3 million in cash and cash equivalents and $902.8 million in marketable securities, totaling $1.07 billion in liquidity (Note 3 and Note 5). Inventory increased to $58.6 million from $43.2 million at year-end 2024 (Note 5). The company has no debt reported in the notes.
Total purchase commitments were $45.6 million as of June 30, 2025 (Note 7), consisting of $18.2 million due in the remainder of 2025, $14.4 million in 2026, and $13.0 million in 2027. These commitments are for supply purchases including software licenses and cloud services. Operating lease liabilities totaled $32.3 million, with $4.7 million current (Note 6).
No share repurchases, dividends, or debt transactions were disclosed. Capital expenditures are reported in the cash flow statement (not part of notes) but the notes do not provide a capex figure.
Astera Labs operates as a single reporting segment (Note 2). The CODM uses net income to assess performance. For the six months ended June 30, 2025, revenue was $351.4 million, cost of revenue $86.4 million, stock-based compensation $77.6 million, personnel-related expenses $86.3 million, and other segment items $18.0 million, resulting in net income of $83.0 million. Geographically, revenue came from Taiwan (38%), China (30%), Singapore (28%), United States (2%), and other (3%). Customer concentration is high; five customers each accounted for 10% or more of revenue in H1 2025.
Net cash provided by operating activities (CFO) was $145.9M for the first half of 2025, a substantial increase from $33.5M in the prior-year period. This growth was driven by a swing to net income of $83.0M (versus a net loss of $100.5M) and significant non-cash adjustments including stock-based compensation of $77.9M (down from $140.8M) and depreciation of $2.5M. Working capital changes provided a net $6.5M source, with a $14.5M decrease in accounts receivable partially offset by a $14.6M inventory build and $18.5M increase in prepaid expenses.
Capital expenditures (capex) totaled $6.6M, up from $2.1M, but remain low relative to CFO, representing only 4.5% of operating cash flow. Investing activities also included net purchases of marketable securities, resulting in net cash used in investing of $67.6M. Financing activities provided $5.1M, primarily from employee stock plan proceeds, with no share repurchases or dividends. The company ended the period with $163.4M in cash, cash equivalents, and restricted cash, up from $80.0M at the start.
Overall, the cash flow profile is healthy with strong operational cash generation, low capex intensity, and no capital returns, indicating ample liquidity for growth initiatives.